Peter D. Gorycki - Concepedia

Author

Peter D. Gorycki

GlaxoSmithKline (United States)ORCID

Also Known As

P D Gorycki, P. D. Gorycki, P. GORYCKI, P. Gorycki, Pete Gorycki, Peter D Gorycki, Peter D. Gorycki, Peter Gorycki

Publications

933

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)New Frontier Research Triangle Park Foundation GlaxoSmithKline (United Kingdom)University of Virginia

About

Peter D. Gorycki is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	333
2	Biochemistry	5	5	232
3	Natural Sciences	2	2	66
4	Engineering	1	1	16
5	Biomolecular Engineering	1	1	16

Peter D. Gorycki

Publications

727

Citations

H-Index

Page 1

	Year	Citations
Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes Jerry L. Adams, Jeffrey C. Boehm, Shouki Kassis, Bioorganic & Medicinal Chemistry Letters BiochemistryMedicineLiver PhysiologyPyrimidinylimidazole InhibitorsHepatotoxicity	1998	113
SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. Don E. Griswold, Edward F. Webb, Alison M. Badger, PubMed InflammationCytokineAnti-inflammatoryInterleukin-4 ProductionMedicine	1998	86
Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer Yanli Deng, Caroline Sychterz, A. Benjamin Suttle, Xenobiotica	2012	83
Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig David C. Underwood, Steven Bochnowicz, Ruth R. Osborn, Journal of Pharmacology and Experimental Therapeutics	1998	70
Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects Yanli Deng, Armina Madatian, Mary Beth Wire, Drug Metabolism and Disposition	2011	54
Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation David A. Bershas, Danièle Ouellet, Donna Mamaril-Fishman, Drug Metabolism and Disposition	2013	45
SB 207499 (Ariflo), a Second Generation Phosphodiesterase 4 Inhibitor, Reduces Tumor Necrosis Factor α and Interleukin-4 Production in vivo Don E. Griswold, Edward F. Webb, Alison M. Badger, Journal of Pharmacology and Experimental Therapeutics	1998	41
Comparison of N,N′-diarylsquaramides and N,N′-diarylureas as antagonists of the CXCR2 chemokine receptor Brent W. McCleland, Roderick S. Davis, Michael R. Palovich, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryFunctional SelectivityNatural SciencesCxcr2 Chemokine Receptor	2006	37
Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor Qi Jin, Hong Nie, Brent W. McCleland, Bioorganic & Medicinal Chemistry Letters BiochemistryMedicineCxcr2 Chemokine ReceptorMechanism Of ActionReceptor (Biochemistry)	2004	37
Inhibition of topoisomerases by fredericamycin A Michael D. Latham, Charles K. King, Peter D. Gorycki, Cancer Chemotherapy and Pharmacology Medicinal ChemistryBiochemistryMedicineNatural SciencesFredericamycin A	1989	29

Page 1